Skip to main content
SpringerLink
Log in

Systemic Absorption and Activity of Recombinant Consensus Interferons After Intratracheal Instillation and Aerosol Administration

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. The pulmonary pharmacokinetics and bioactivity of E. coli derived recombinant consensus interferon (CIFN) and a modified lactose-conjugated consensus interferon (LacCIFN) were evaluated in animals.

Methods. Estimated doses of 20 and 100 µg/kg of the interferons were administered to anesthetized rats by aerosol via ultrasonic nebulizer as well as intravenous injection. Rats also received nominal doses of 50 and 200 µg/kg via intratracheal instillation (IT). Hamsters were treated with interferon via various routes including IT. The effectiveness of treatment was assessed by the resistance to development of hind leg paralysis following infection with encephalomyocarditis virus.

Results. Significant amounts of CIFN and LacCIFN were found in rat plasma after aerosol administration. Peak plasma levels occurred ≈25–30 minutes with estimated bioavailabilities approaching 70%. Absorption of CIFN was rate limiting and plasma levels were detectable 12 hr post-dose. The CIFN at IT doses as low as 5 µg/kg was effective at reducing paralysis in hamsters but protection was variable and doses of up to 100 µg/kg were not 100% effective.

Conclusions. Despite the incomplete protection, the results demonstrate the feasibility of treating systemic viral infections with interferon administered directly to the lungs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. M. L. Klein, T. D. Bartley, P. H. Lai, and H. S. Lu. Structural characterization of recombinant consensus interferon-alpha. J. Chromatogr. 454: 205–215, 1988.

    Google Scholar 

  2. M. L. Klein, T. D. Bartley, J. M. Davis, D. W. Whiteley, and H. S. Lu. Isolation and structural characterization of three isoforms of recombinant consensus alpha interferon. Arch. Biochem. Biophys. 276: 531–537, 1990.

    Google Scholar 

  3. V. Bocci, G. P. Pessina, A. Pacini, L. Paulesu, M. Muscettola, and K. E. Mogensen. Pulmonary catabolism of interferons: alveolar absorption of 125I-labeled human interferon alpha is accompanied by partial loss of biological activity. Antiviral Res. 4: 211–220, 1984.

    Google Scholar 

  4. V. Kinnula, K. Mattson, and K. Cantell. Pharmacokinetics and toxicity of inhaled human interferon-alpha in patients with lung cancer. J. Interferon Res. 9: 419–423, 1989.

    Google Scholar 

  5. J. S. Patton, P. Trinchero, and R. M. Platz. Bioavailability of pulmonary delivery peptides and proteins: α-interferon, calcitonins and parathyroid hormone. J. Con. Rel. 28: 79–85, 1994.

    Google Scholar 

  6. B. W. Altrock, K. D. Fagin, H. R. Hockman, E. N. Fish, L. Goldstein, D. Chang, K. Duker, and N. Stebbing. Antiviral and antitumor effects of a human interferon analog, IFN-αCon1, assessed in hamsters. J. Interferon Res. 6: 405–415, 1986.

    Google Scholar 

  7. J. L. Liu, B. Peterson, K. L. Whitcomb, M. Woodward, C. Ransone, K. Pippo, D. C. Collins, and A. D. Habberfield. Liver-targeted recombinant consensus interferon. J. Biol. Chem. In review, 1995.

  8. R. W. Niven, A. Y. Ip, C. Ransome, H. Silvers, and T. Arakawa. Stability of recombinant consensus interferon (rCon-IFN) to air-jet and ultrasonic nebulization. J. Pharm. Sci. 84: 1210–1214, 1995.

    Google Scholar 

  9. R. W. Niven, K. L. Whitcomb, O. B. Kinstler, A. Y. Ip, and L. Shaner. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm. Res. 12: 1143–1349, 1995.

    Google Scholar 

  10. R. W. Niven, F. D. Lott, and J. M. Cribbs. Pulmonary absorption of recombinant methionyl human granulocyte colony stimulating factor (r-huG-CSF) after intratracheal instillation to the hamster. Pharm. Res. 10: 1604–10, 1993.

    Google Scholar 

  11. R. W. Niven, F. D. Lott, A. Y. Ip, and J. M. Cribbs. Pulmonary delivery of powders and solutions containing granulocyte colony-stimulating factor (rhG-CSF) to the rabbit. Pharm. Res. 11: 1101–1109, 1993.

    Google Scholar 

  12. R. W. Niven, K. L. Whitcomb, L. Shaner, L. D. Ralph, A. D. Habberfield, and J. V. Wilson. Pulmonary absorption of polyethylene glycolated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF). J. Con. Rel. 32: 177–189, 1994.

    Google Scholar 

  13. S. Kobayashi, S. Kondo, and K. Juni. Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers. Pharm. Res. 11: 1239–1243, 1994.

    Google Scholar 

  14. P. Colthorpe, S. J. Farr, I. J. Smith, D. Wyatt, and G. Taylor. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth-hormone in rabbits. Pharm. Res. 12: 356–359, 1995.

    Google Scholar 

  15. P. Colthorpe, S. J. Farr, G. Taylor, I. J. Smith, and D. Wyatt. The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm. Res. 9: 764–768, 1992.

    Google Scholar 

  16. K. G. Rice, O. A. Weisz, T. Barthel, R. T. Lee, and Y. C. Lee. Defined geometry of binding between triantennary glycopeptide and the asialoglycoprotein receptor of rat heptocytes. J. Biol. Chem. 265: 18429–18434, 1990.

    Google Scholar 

  17. J. D. Brain, D. E. Knudson, S. P. Sorokin, and M. A. Davis. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ. Res. 11: 13–33, 1976.

    Google Scholar 

  18. J. O. Ford, R. F. Dodson, and M. G. Williams, Jr. An ultrastructural study of the blood/air barrier in the guinea-pig. Tissue Cell 16: 53–63, 1984.

    Google Scholar 

  19. O. S. Atwal, L. Viel, and K. J. Minhas. An uptake of cationized ferritin by alveolar type I cells in airway-instilled goat lung: distribution of anionic sites on the epithelial surface. J. Submicrosc. Cytol. Pathol. 22: 425–432, 1990.

    Google Scholar 

  20. J. Gil, D. A. Silage, and J. M. McNiff. Distribution of vesicles in cells of air-blood barrier in the rabbit. J. Appl. Physiol. 50: 334–340, 1981.

    Google Scholar 

  21. M. C. Williams. Endocytosis in alveolar type II cells: effect of charge and size of tracers. Proc. Natl. Acad. Sci. USA 81: 6054–6058, 1984.

    Google Scholar 

  22. B. T. Peterson, and K. D. Dickerson. Concentration of aerosolized 99mTc-albumin in the pulmonary lymph of anesthetized sheep. J. Appl. Physiol. 68: 1233–1240, 1990.

    Google Scholar 

  23. P. Maasilta, M. Halme, K. Mattson, and K. Cantell. Pharmacokinetics of inhaled recombinant and natural alpha interferon [letter]. Lancet 337: 371, 1991.

    Google Scholar 

Download references

Authors
  1. Ralph W. Niven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Lane Whitcomb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melissa Woodward
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jennifer Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Concesa Jornacion
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niven, R.W., Whitcomb, K.L., Woodward, M. et al. Systemic Absorption and Activity of Recombinant Consensus Interferons After Intratracheal Instillation and Aerosol Administration. Pharm Res 12, 1889–1895 (1995). https://doi.org/10.1023/A:1016279503631

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016279503631

Search

Navigation